Medtronic to Feature FDA Approved Endeavor Stent at ACC
March 11, 2008 – Medtronic Inc. will feature its newly FDA-cleared Endeavor Zotarolimus-Eluting Coronary Stent System (Endeavor) at the American College of Cardiology's 57th Annual Scientific Session, from March 29-April 1, in Chicago, IL, marking a major development in the field of interventional cardiology for the company.
Endeavor is engineered for the treatment of coronary artery disease. The stent’s design combines a stent platform with the drug zotarolimus and a biocompatible polymer.
“This device addresses an important need by demonstrating comparable clinical effectiveness to a first generation drug-eluting stent while also exhibiting a safety profile more typical of a bare-metal stent, long considered a benchmark for safety performance. In addition, it has the advantage of being exceptionally easy to deliver through the tortuous vessels of the coronary vasculature. For these reasons, the Endeavor stent will undoubtedly be a welcome addition to the practice of interventional cardiology in the United States,” said Dr. Martin B. Leon, professor of medicine at Columbia University Medical Center in New York, cardiologist at New York-Presbyterian Hospital/Columbia University Medical Center, founder and chairman emeritus of the Cardiovascular Research Foundation, and principal investigator of the ENDEAVOR III and IV clinical trials.
The ENDEAVOR clinical program includes seven studies: three randomized controlled trials and four registries. Medtronic’s FDA submission included clinical data on more than 2,100 patients treated with the Endeavor stent, 1,287 of whom were studied to two years and 675 to three years.
For more information: www.endeavorstent.com
More like this
- Endeavor Zotarolimus-Eluting Stent Offered for Treatment of Coronaries
- Medtronic Starts U.S. Study Comparing Safety of Endeavor, Cypher Drug-Eluting Stents
- New Trial Compares 'Olimus'-Eluting Coronary Stents
- European Study of Different Olimus-Eluting Stents Starts Today
- Clinical Efficacy Promising at One-Year for ENDEAVOR IV